Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Catalent, Inc
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
Government offers help securing supplies in return for another 100 million doses by Q2. That would mean abandoning Pfizer’s preferred arms-length relationship.
Catalent has announced the launch of a new technology, OptiGel DR, for the formulation and manufacture of delayed/enteric release softgels, offering advantages such as potentially enhancing bioavailability and reducing gastric reflux effects.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
- Contract Research, Toxicology Testing-CRO
- OTC, Consumer
- Controlled Release
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Accucaps Industries Limited
- Catalent U.K. Swindon Zydis Limited
- Cook Pharmica LLC
- Juniper Pharmaceuticals
- Molecular Profiles Ltd.
- Columbia Laboratories, Inc.